retatrutide - Search News

Lilly, Phase 3 and Retatrutide

Lilly’s Retatrutide Scores Triple Trial Triumph With 26% Weight Loss, But New Safety Signal Emerges

Analysts were hoping for a safety profile similar to what was achieved in Phase II but an abnormal sense of touch, called dysesthesia, has emerged in the late-stage TRIUMPH-4 trial.

Continue reading

Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial

InvestorsHub on MSN · 2d

Eli Lilly shares rise after retatrutide delivers striking weight-loss and pain-relief results in phase 3 study

1d

People Are Already Taking This Unapproved New Weight-Loss Drug

Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...

Retatrutide confers up to 28.7% weight loss, reduction in knee osteoarthritis pain

A novel triple receptor agonist conferred weight loss of up to 28.7% at 68 weeks and reductions in pain for adults with ...

Lilly’s three-pronged drug puts obesity field ‘on notice’

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...

Zacks.com on MSN

Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win

LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results